{"analyses":[{"ciNumSides":"TWO_SIDED","groupDescription":"Week 12","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.005","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Week 12","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.004","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Week 24","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.002","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalMethod":"ANCOVA"},{"ciNumSides":"TWO_SIDED","groupDescription":"Week 24","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.026","pValueComment":"a priori p-value significance threshold: 2-sided ≤0.05","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.5","value":"5.9"},{"groupId":"OG001","spread":"10.0","value":"8.8"},{"groupId":"OG002","spread":"9.9","value":"8.5"}]}],"title":"Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"10.7","value":"6.6"},{"groupId":"OG001","spread":"10.4","value":"8.8"},{"groupId":"OG002","spread":"10.7","value":"9.7"}]}],"title":"Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"170"},{"groupId":"OG001","value":"170"},{"groupId":"OG002","value":"174"}],"units":"Participants"}],"description":"The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Scale is a brief 13-item, symptom-specific questionnaire that specifically assesses the participant's self-reported severity of fatigue and its impact upon daily activities and functioning. The FACIT-F uses a numeric rating scale of 0 (Not at all) to 4 (Very much) for each item to assess fatigue and its impact in the past 7 days. Total scores range from 0 to 52, with higher scores indicating less fatigue.","dispersionType":"Standard Deviation","groups":[{"description":"Placebo administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG000","title":"Placebo"},{"description":"Baricitinib 2 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG001","title":"Baricitinib 2 mg"},{"description":"Baricitinib 4 mg administered PO QD through Week 24. Participants continued to take background cDMARD therapy throughout study.","id":"OG002","title":"Baricitinib 4 mg"}],"paramType":"MEAN","populationDescription":"mITT population includes all randomized participants who received at least 1 dose of the study drug. Participants were analyzed according to the study drug to which they were randomized. Missing values due to discontinuation of study or drug, rescue, or missing data were imputed using mLOCF.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12, Week 24","title":"Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue Scale Scores","type":"SECONDARY","unitOfMeasure":"Units on a Scale"}